

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent No.: 7,148,226)
Application No.: 10/718,337)
Confirmation No.: 9247)
Inventors: Allen BORCHARDT et al.)
Issue Date.: December 12, 2006)

For: INHIBITORS OF HEPATITIS C VIRUS
RNA-DEPENDENT RNA POLYMERASE,
AND COMPOSITIONS AND TREATMENTS
USING THE SAME

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

REQUEST FOR CERTIFICATE OF CORRECTION

Pursuant to 35 U.S.C. § 254, and 37 C.F.R. § 1.322, this is a request for a Certificate of Correction in the above-identified patent. The mistakes identified in the appended Form occurred through the fault of the Patent Office, as clearly disclosed by the records of the application which matured into this patent.

Two (2) copies of PTO Form 1050 are appended. The complete Certificate of Correction involves six (6) pages. Issuance of the Certificate of Correction containing the correction is earnestly requested. Since these changes are necessitated through no fault of the Applicants, no fee is believed to be associated with this request. Nonetheless, should the Patent and Trademark Office determine that a fee is required, please charge Deposit Account No. 500329.

Respectfully submitted,

Dated: January 5, 2007

By: /Jeffrey H. Tidwell/
Jeffrey H. Tidwell
Reg. No. 47,995

UNITED STATES AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

Page 1 of 6

PATENT NO. : 7,148,226

APPLICATION NO.: 10/718,337

ISSUE DATE : December 12, 2006

INVENTOR(S) : Allen BORCHARDT et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims, Claim 1, Column 457, Line 3:

Please delete "R⁶" and insert - R⁶ -

In the Claims, Claim 7, Column 457, Line 66:

Please delete "R⁵-O-" and insert - R⁶-O- --

In the Claims, Claim 8, Column 458, Line 28:

Please delete "R⁵" and insert - R⁶ -

In the Claims, Claim 15, Column 459, Line 32:

Please delete "R⁶-O-" and insert - R⁶-O- --

In the Claims, Claim 23, Column 460, Lines 65 - 67:

Please delete "6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]4-hydroxy-5,6-dihydro-pyran-2-one" and insert - 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]4-hydroxy-5,6-dihydro-pyran-2-one --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Pfizer Inc.

10555 Science Center Drive
San Diego, CA 92121

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (or by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 2 of 6

PATENT NO. : 7,148,226

APPLICATION NO.: 10/718,337

ISSUE DATE : December 12, 2006

INVENTOR(S) : Allen BORCHARDT et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims, Claim 23, Column 461, Lines 1 – 3:

Please delete "6-[2-(3-tert-Butyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one" and insert – 6-[2-(3-tert-Butyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one –

In the Claims, Claim 23, Column 461, Lines 4 – 6:

Please delete "6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one" and insert – 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one –

In the Claims, Claim 23, Column 461, Lines 10 – 12:

Please delete "6-cyclopentyl-3-[(5,7-dimethyl [1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-isopropylphenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione" and insert – 6-cyclopentyl-3-[(5,7-dimethyl [1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-isopropylphenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione –

In the Claims, Claim 23, Column 461, Lines 34 – 36:

Please delete "6-[2-(3-Chloro-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one" and insert – 6-[2-(3-Chloro-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one –

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Pfizer Inc.

10555 Science Center Drive

San Diego, CA 92121

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

UNITED STATES AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTIONPage 3 of 6

PATENT NO. : 7,148,226

APPLICATION NO.: 10/718,337

ISSUE DATE : December 12, 2006

INVENTOR(S) : Allen BORCHARDT et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims, Claim 23, Column 461, Lines 37 – 39:

Please delete "6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one" and insert -- 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one –

In the Claims, Claim 23, Column 461, Lines 56 – 58:

Please delete "6-[2-(3-chloro-4-methoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1H-benzimidazol-2-yl)thio]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one" and insert -- 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1H-benzimidazol-2-yl)thio]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one –

In the Claims, Claim 23, Column 462, Lines 8 – 10:

Please delete "6-cyclopentyl-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-fluoro-4-isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one" and insert -- 6-cyclopentyl-3-[(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-fluoro-4-isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one –

In the Claims, Claim 23, Column 462, Lines 14 – 16:

Please delete "6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one" and insert -- 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one –

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Pfizer Inc.

10555 Science Center Drive
San Diego, CA 92121

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria VA 2313-1450.

UNITED STATES AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTIONPage 4 of 6

PATENT NO. : 7,148,226

APPLICATION NO.: 10/718,337

ISSUE DATE : December 12, 2006

INVENTOR(S) : Allen BORCHARDT et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims, Claim 23, Column 462, Lines 48 – 50:

Please delete "6-Cyclopentyl-6-[2-(3ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-3-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one" and insert – 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-3-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one –

In the Claims, Claim 23, Column 462, Lines 60 – 63:

Please delete "N-[2-[4-(2-(2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-hydroxy-6-oxo-3,6-dehydro-2H-pyran-2-yl]ethyl)-2-ethylphenoxy]ethyl]acetamide" and insert – N-[2-[4-(2-(2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]ethyl)-2-ethylphenoxy]ethyl]acetamide –

In the Claims, Claim 23, Column 463, Lines 12 – 15:

Please delete "6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one" and insert – 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one –

In the Claims, Claim 23, Column 463, Lines 16 – 19:

Please delete "(+)-2-(2-chloro-4-[2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl]-phenyl)-methyl-propionitrile" and insert – (+)-2-(2-chloro-4-[2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl]-phenyl)-2-methyl-propionitrile –

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Pfizer Inc.

10555 Science Center Drive

San Diego, CA 92121

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria VA 2313-1450.

UNITED STATES AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTIONPage 5 of 6

PATENT NO. : 7,148,226

APPLICATION NO.: 10/718,337

ISSUE DATE : December 12, 2006

INVENTOR(S) : Allen BORCHARDT et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims, Claim 23, Column 463, Lines 24 – 27:

Please delete "(+)-2-4-[2-{2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluorophenyl)-2-methylpropionitrile" and insert – (-)-2-(4-[2-{2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluorophenyl)-2-methylpropionitrile –

In the Claims, Claim 23, Column 463, Lines 28 – 31:

Please delete "(-)-2-(4-[2-{2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluorophenyl)-2-methylpropionitrile" and insert – (-)-2-(4-[2-{2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl}-2-fluorophenyl)-2-methylpropionitrile –

In the Claims, Claim 23, Column 463, Lines 35 – 38:

Please delete "(-)-3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-hydroxy-5,6-dihydro-2H-pyran-2-one" and insert – (-)-3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one –

In the Claims, Claim 23, Column 463, Lines 51 – 53:

Please delete "6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one" and insert – 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one –

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Pfizer Inc.

10555 Science Center Drive

San Diego, CA 92121

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria VA 2313-1450.

UNITED STATES AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTIONPage 6 of 6

PATENT NO. : 7,148,226

APPLICATION NO.: 10/718,337

ISSUE DATE : December 12, 2006

INVENTOR(S) : Allen BORCHARDT et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims, Claim 23, Column 463, Lines 61 – 63:

Please delete "6-Cyclopentyl-6-[2-(3-cyclopropyl-4-methoxy-phenyl)-ethyl]-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one" and insert – 6-Cyclopentyl-6-[2-(3-cyclopropyl-4-methoxy-phenyl)-ethyl]-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one –

In the Claims, Claim 24, Column 464, Lines 22 – 25:

Please delete "(+)-2-(4-(2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl)-2-fluoro-phenyl)-2-methyl-propionitrile" and insert – (+)-2-(4-(2-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl)-2-fluoro-phenyl)-2-methyl-propionitrile –

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Pfizer Inc.

10555 Science Center Drive

San Diego, CA 92121

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

UNITED STATES AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTIONPage 1 of 6

PATENT NO. : 7,148,226

APPLICATION NO.: 10/718,337

ISSUE DATE : December 12, 2006

INVENTOR(S) : Allen BORCHARDT et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims, Claim 1, Column 457, Line 3:

Please delete "R⁸" and insert - R⁶ -

In the Claims, Claim 7, Column 457, Line 66:

Please delete "R⁵-O-" and insert - R⁵-O- -

In the Claims, Claim 8, Column 458, Line 28:

Please delete "R⁵" and insert - R⁶ -

In the Claims, Claim 15, Column 459, Line 32:

Please delete 'R⁸-O-' and insert - R⁵-O- -

In the Claims, Claim 23, Column 460, Lines 65 - 67:

Please delete "6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]4-hydroxy-5,6-dihydro-pyran-2-one" and insert - 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]4-hydroxy-5,6-dihydro-pyran-2-one --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Pfizer Inc.

10555 Science Center Drive
San Diego, CA 92121

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 4.5 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria VA 2313-1450.

UNITED STATES AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTIONPage 2 of 6

PATENT NO. : 7,148,226

APPLICATION NO.: 10/718,337

ISSUE DATE : December 12, 2006

INVENTOR(S) : Allen BORCHARDT et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims, Claim 23, Column 461, Lines 1 – 3:

Please delete "6-[2-(3-tert-Butyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one" and insert – 6-[2-(3-tert-Butyl-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one –

In the Claims, Claim 23, Column 461, Lines 4 – 6:

Please delete "6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one" and insert – 6-[2-(3-Chloro-4-isopropoxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one –

In the Claims, Claim 23, Column 461, Lines 10 – 12:

Please delete "6-cyclopentyl-3-[5-(7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-isopropylphenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione" and insert – 6-cyclopentyl-3-[5-(7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-isopropylphenyl)ethyl]dihydro-2H-pyran-2,4(3H)-dione –

In the Claims, Claim 23, Column 461, Lines 34 – 36:

Please delete "6-[2-(3-Chloro-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one" and insert – 6-[2-(3-Chloro-4-hydroxy-phenyl)-ethyl]-6-cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one –

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Pfizer Inc.
10555 Science Center Drive
San Diego, CA 92121

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

UNITED STATES AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTIONPage 3 of 6

PATENT NO. : 7,148,226

APPLICATION NO.: 10/718,337

ISSUE DATE : December 12, 2006

INVENTOR(S) : Allen BORCHARDT et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims, Claim 23, Column 461, Lines 37 – 39:

Please delete "6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one" and insert – 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-4-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one –

In the Claims, Claim 23, Column 461, Lines 56 – 58:

Please delete "6-[2-(3-chloro-4-methoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1H-benzimidazol-2-yl)thio]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one" and insert – 6-[2-(3-chloro-4-methoxyphenyl)ethyl]-3-[(5-chloro-1-methyl-1H-benzimidazol-2-yl)thio]-6-cyclopentyl-4-hydroxy-5,6-dihydro-2H-pyran-2-one –

In the Claims, Claim 23, Column 462, Lines 8 – 10:

Please delete "6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-fluoro-4-isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one" and insert – 6-cyclopentyl-3-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-[2-(3-fluoro-4-isopropoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one –

In the Claims, Claim 23, Column 462, Lines 14 – 16:

Please delete "6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one" and insert – 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(3-ethyl-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one –

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Pfizer Inc.

10555 Science Center Drive
San Diego, CA 92121

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

UNITED STATES AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTIONPage 4 of 6

PATENT NO. : 7,148,226

APPLICATION NO.: 10/718,337

ISSUE DATE : December 12, 2006

INVENTOR(S) : Allen BORCHARDT et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims, Claim 23, Column 462, Lines 48 – 50:

Please delete "6-Cyclopentyl-6-[2-(3ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-3-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one" and insert – 6-Cyclopentyl-6-[2-(3-ethyl-4-hydroxy-phenyl)-ethyl]-4-hydroxy-3-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-5,6-dihydro-pyran-2-one –

In the Claims, Claim 23, Column 462, Lines 60 – 63:

Please delete "N-[2-{4-(2-(2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-hydroxy-6-oxo-3,6-dehydro-2H-pyran-2-yl)ethyl}-2-ethylphenoxy]ethyl]acetamide" and insert – N-[2-{4-(2-(2-cyclopentyl-5-[(5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-4-hydroxy-6-oxo-3,6-dehydro-2H-pyran-2-yl)ethyl}-2-ethylphenoxy]ethyl]acetamide –

In the Claims, Claim 23, Column 463, Lines 12 – 15:

Please delete "6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one" and insert – 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-4-hydroxy-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one –

In the Claims, Claim 23, Column 463, Lines 16 – 19:

Please delete "(+)-2-(2-chloro-4-[2-(2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl)-ethyl]-phenyl)-methyl-propionitrile" and insert -- (+)-2-(2-chloro-4-[2-(2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl)-ethyl]-phenyl)-2-methyl-propionitrile –

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Pfizer Inc.

10555 Science Center Drive

San Diego, CA 92121

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

UNITED STATES AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTIONPage 5 of 6

PATENT NO. : 7,148,226

APPLICATION NO.: 10/718,337

ISSUE DATE : December 12, 2006

INVENTOR(S) : Allen BORCHARDT et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims, Claim 23, Column 463, Lines 24 – 27:

Please delete "(+)-2-4-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl]-2-fluorophenyl)-2-methylpropionitrile" and insert -(+)-2-(4-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl]-2-fluorophenyl)-2-methylpropionitrile –

In the Claims, Claim 23, Column 463, Lines 28 – 31:

Please delete "(-)-2-(4-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl]-2-fluorophenyl)-2-methylpropionitrile" and insert --(-)-2-(4-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl]-ethyl]-2-fluorophenyl)-2-methylpropionitrile –

In the Claims, Claim 23, Column 463, Lines 35 – 38:

Please delete "(-)-3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-hydroxy-5,6-dihydro-2H-pyran-2-one" and insert --(-)-3-[(6-chloro[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl]-6-cyclopentyl-6-[2-(5-ethyl-4-hydroxy-2-methoxyphenyl)ethyl]-4-hydroxy-5,6-dihydro-2H-pyran-2-one –

In the Claims, Claim 23, Column 463, Lines 51 – 53:

Please delete "6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one" and insert -- 6-Cyclopentyl-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-6-[2-(5-ethyl-2-methoxy-phenyl)-ethyl]-4-hydroxy-5,6-dihydro-pyran-2-one –

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Pfizer Inc.

10555 Science Center Drive

San Diego, CA 92121

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Filing will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

UNITED STATES AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTIONPage 6 of 6

PATENT NO. : 7,148,226

APPLICATION NO.: 10/718,337

ISSUE DATE : December 12, 2006

INVENTOR(S) : Allen BORCHARDT et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims, Claim 23, Column 463, Lines 61 – 63:

Please delete "6-Cyclopentyl-6-[2-(3-cyclopropyl-4-methoxy-phenyl)-ethyl]-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one" and insert – 6-Cyclopentyl-6-[2-(3-cyclopropyl-4-methoxy-phenyl)-ethyl]-3-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4-hydroxy-5,6-dihydro-pyran-2-one –

In the Claims, Claim 24, Column 464, Lines 22 – 25:

Please delete "(+)-2-(4-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl)-2-fluoro-2-methyl-propionitrile" and insert – (+)-2-(4-[2-Cyclopentyl-5-(6-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylmethyl)-4,6-dioxo-tetrahydro-pyran-2-yl]-ethyl)-2-fluoro-phenyl)-2-methyl-propionitrile –

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Pfizer Inc.
10555 Science Center Drive
San Diego, CA 92121

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 C.F.R. 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.